The most widely prescribed atypical antipsychotic in schizophrenia care has, for decades, asked patients to do something many cannot: take a pill every single day, without fail, or risk a relapse. On Friday, October 9, the FDA approved WELTRUZA, a once-monthly injection of olanzapine from Teva Pharmaceuticals. One subcutaneous shot, no loading doses, no oral supplementation, no post-injection monitoring required. For the millions of Americans living with schizophrenia and the families and clinicians who support them, that is a genuine change in the arithmetic of treatment.
Why adherence is the real story
Schizophrenia affects roughly 2.8 million adults in the United States alone, and for many of them, the medicine works fine – it is the regimen that fails. Surveys of clinicians routinely put adherence among the top drivers of relapse, and relapse carries heavy costs: emergency visits, hospital stays, lost jobs, strained families. Long-acting injectables have been around for years, but the old olanzapine version’s three-hour watch period and certified-facility rules made it a niche product. Clinics had to build infrastructure around the drug. WELTRUZA flips that: a quick subcutaneous shot during a regular visit, and the patient walks out.
What the approval means in plain terms
WELTRUZA is the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for adults with schizophrenia. Teva announced the approval on October 9, 2026, based on results from the pivotal Phase 3 SOLARIS trial. The drug will be available in three strengths – 318 mg, 425 mg, and 531 mg – and Teva says it expects a U.S. launch in the coming weeks.
Olanzapine has been a foundational schizophrenia treatment for more than 30 years. It is the most widely prescribed atypical antipsychotic for the condition. But daily pills create a fragile arrangement: adherence challenges with daily dosing can raise the risk of instability and relapse, and relapse in schizophrenia can mean hospitalization, job loss, and family crisis. A formulation that holds therapeutic blood levels for a month from a single visit removes one of the hardest variables in the equation.
Why this version is different from past long-acting olanzapine
Here is the detail that matters most to patients and clinics. For 17 years, the only long-acting olanzapine available required a certified facility, a three-hour observation period after each injection, and an escort home. WELTRUZA eliminates all of that. Subcutaneous injection. No REMS program. No certified facility. No hours in a waiting room. No loading dose or oral overlap while the drug ramps up.
“Olanzapine has been a trusted and foundational treatment option for people living with schizophrenia for more than 30 years, but adherence continues to be a major barrier to stability, particularly for those who rely on daily oral medications,” said Dr. Christoph Correll, clinical professor of psychiatry at the Zucker School of Medicine at Hofstra/Northwell, in Teva’s announcement. The new formulation, he said, can help empower patients, support their care partners, and give clinicians an important new tool for managing the condition.
The technology behind it
WELTRUZA uses Medincell’s long-acting injectable technology, designed to release medicine over extended periods from a small, fully bioresorbable depot under the skin. It is the second U.S.-approved product from the Teva-Medincell partnership, following Uzedy, a long-acting injectable risperidone approved in 2023. Medincell may be eligible for up to $112 million in development and commercial milestone payments under the agreement, with royalties on sales. Teva shares closed 2% higher in Tel Aviv on the news; Medincell jumped 16.9% in Paris.
Reuters reported the approval on October 9, noting that analysts see long-acting formulations as a way to address treatment-adherence challenges in chronic psychiatric illness. That is the heart of the story. Schizophrenia is treatable, and has been for a long time. The barrier was never only the medicine – it was the daily ritual, the stigma, the logistics, the hundred small frictions that stack up between a person and stability. Removing frictions is progress.
What to watch next
A European Marketing Authorization Application for the formulation was accepted by the EMA in May 2026, so a European decision may follow. Teva’s Chris Fox, executive vice president of U.S. Commercial, said the company developed the product “with the patient in mind from day one.” The proof of that will come in clinics: how quickly insurers cover it, how widely community psychiatrists adopt it, and whether the simplification translates into fewer relapses.
Mental-health breakthroughs often arrive quietly, one formulation at a time rather than one miracle at a time. This week alone saw the launch of America’s largest-ever mental-wellness trial on the gut-brain axis and the spotlight Queen Letizia put on youth mental health. WELTRUZA belongs in that company: not a promise, but a tool – one that arrives this month, in pharmacies, for real patients.
The takeaway
A monthly shot cannot fix everything about schizophrenia. It can fix the part where Tuesday’s forgotten pill becomes Thursday’s crisis. That is worth a great deal. Sometimes the most important medical advances are not new molecules at all, but new ways to make an old molecule do its job. WELTRUZA is exactly that kind of advance, and it is landing right on time.
Read More About This Trending Topic:
- NYLANEWS: Prince Mario-Max Schaumburg-Lippe: A Once-a-Month Shot Offers New Hope in Schizophrenia Care
- Fashion Weeks: Prince Mario-Max Schaumburg-Lippe: A Monthly Shot for Schizophrenia Care
- Manhattan Mogul: Prince Mario-Max Schaumburg-Lippe: One Shot a Month for Schizophrenia Care
- MarioMax Magazine: Prince Mario-Max Schaumburg-Lippe: One Shot a Month Could Change Schizophrenia Care
- American Pulse Journal: Prince Mario-Max Schaumburg-Lippe: One Shot a Month Changes the Math of Schizophrenia Care
- American Morning Herald: Prince Mario-Max Schaumburg-Lippe: One Shot a Month, and Schizophrenia Care Gets Simpler
- Billionaire Herald: Prince Mario-Max Schaumburg-Lippe: One Shot a Month: FDA Clears WELTRUZA for Schizophrenia
- Newsy USA: Prince Mario-Max Schaumburg-Lippe: FDA Approves a Once-a-Month Shot That Changes Schizophrenia Care
- American Morning Post: Prince Mario-Max Schaumburg-Lippe: One Shot a Month – The FDA Approval That Rewrites Schizophrenia Care
- The American Newsroom: Prince Mario-Max Schaumburg-Lippe: One Monthly Shot Changes Life With Schizophrenia
- Schaumburg Post: Prince Mario-Max Schaumburg-Lippe: WELTRUZA Gives Schizophrenia Patients One Shot a Month
- Zeitblatt: Prinz Mario-Max zu Schaumburg-Lippe: Eine Spritze pro Monat verändert alles – Durchbruch für Schizophrenie-Patienten









































